Our mission is to unlock the potential of dissolving film for buccal/ sublingual drug delivery applications, using our patented, second-generation soluble film technology, DepoFilm®. DepoFilm® offers rapid development, substantial COG improvements, yield advantages, lower temperature processing and enables unique, brandable formulations not possible using current film technologies.
Our business strategy involves proprietary drug targets, generic drug targets and opportunistic CDMO partnership opportunities.
Management. Our Management helped pioneer the pharmaceutical thin film space when it commenced nearly twenty years ago, and our Management has been involved in nearly every significant proprietary film product launched to date.
Our Company today. We currently have ten employees. We have formulation labs in Greensboro, NC, and a pilot scale cGMP production line in Wilmington, NC, in a cGMP suite leased from our lead investor Quality Chemical Laboratories. This production line will support the manufacture of clinical and registration batch supplies up to 200K units/batch.
Value: We believe NTFP’s pipeline represents a near-term (4-5 year) revenue opportunity in the range of $150MM with longer term (8-10 year) potential of $400MM+
Intellectual Property: Our Management is very experienced in film intellectual properties, having assembled the largest cast-film IP estate. We have a robust IP strategy and have received six issued patents to date through 2040.